Login to Your Account

Basilea Shares Rise On NDA, Alitretinoin Phase III Data

By Cormac Sheridan

Wednesday, May 23, 2007
Basel, Switzerland-based Basilea and its development partner, Johnson & Johnson, disclosed recently they had filed a new drug application for Ceftobiprole, a broad-spectrum cephalosporin antibiotic, for treatment of complicated skin and skin structure infection (cSSSI). A U.S. drug launch could follow early next year. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription